| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
新霉素对铜绿假单胞菌和厌氧菌有效，但对大多数革兰氏阴性菌无效。它对金黄色葡萄球菌的增强功效有时仅限于革兰氏细菌，但长期使用会导致细菌致病性[1]。
|
|---|---|
| 参考文献 | |
| 其他信息 |
Neomycin Sulfate is the sulfate salt form of neomycin, a broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.
Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis. See also: Neomycin Sulfate (annotation moved to). |
| 精确质量 |
614.312
|
|---|---|
| CAS号 |
1405-10-3
|
| 相关CAS号 |
Framycetin;119-04-0
|
| PubChem CID |
62403
|
| 外观&性状 |
White to light yellow solid powder
|
| 沸点 |
1046.1ºC at 760 mmHg
|
| 熔点 |
>187°C (dec.)
|
| 闪点 |
586.5ºC
|
| 蒸汽压 |
0mmHg at 25°C
|
| 折射率 |
56 ° (C=10, H2O)
|
| tPSA |
436.09
|
| 氢键供体(HBD)数目 |
15
|
| 氢键受体(HBA)数目 |
23
|
| 可旋转键数目(RBC) |
9
|
| 重原子数目 |
47
|
| 分子复杂度/Complexity |
953
|
| 定义原子立体中心数目 |
18
|
| SMILES |
S(=O)(=O)(O[H])O[H].O([C@]1([H])[C@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])N([H])[H])O[H])[C@]1([H])[C@]([H])([C@@]([H])(C([H])([H])[C@]([H])([C@@]1([H])O[C@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])N([H])[H])N([H])[H])N([H])[H])O[H]
|
| InChi Key |
OIXVKQDWLFHVGR-GQTDVWSESA-N
|
| InChi Code |
InChI=1S/C23H46N6O13.H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;(H2,1,2,3,4)/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22?,23+;/m1./s1
|
| 化学名 |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid
|
| 别名 |
Framycetin Neomycin BNeomycinMycifradin Soframycin
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。 |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
H2O : ~250 mg/mL (~275.06 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: 50 mg/mL (55.01 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。
请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05593601 | RECRUITING | Drug: Neomycin | Colonization, Asymptomatic | Mahidol University | 2022-11-24 | Phase 4 |
| NCT01227863 | UNKNOWN STATUS | Drug: MAXINOM® Drug: Maxitrol® |
Acute Bacterial Conjunctivitis |
Azidus Brasil | 2011-02 | Phase 3 |
| NCT05779254 | RECRUITING | Drug: Neomycin Sulfate | Anastomotic Leak Microbial Colonization |
Uzsoki Hospital | 2023-02-01 | |
| NCT02001909 | COMPLETED | Drug: Regorafenib (Stivarga, BAY73-4506) Drug: Neomycin |
Neoplasms | Bayer | 2013-12 | Phase 1 |
| NCT00534391 | UNKNOWN STATUS | Drug: neomycin sulfate, polymyxin B sulfate and gramicidin Drug: Artificial tear |
Hordeolum | Chulalongkorn University | 2007-09 | Phase 3 |
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
粤公网安备 44011102003439号